Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 213

1.

Aspirin or enoxaparin thromboprophylaxis for patients with newly diagnosed multiple myeloma treated with lenalidomide.

Larocca A, Cavallo F, Bringhen S, Di Raimondo F, Falanga A, Evangelista A, Cavalli M, Stanevsky A, Corradini P, Pezzatti S, Patriarca F, Cavo M, Peccatori J, Catalano L, Carella AM, Cafro AM, Siniscalchi A, Crippa C, Petrucci MT, Yehuda DB, Beggiato E, Di Toritto TC, Boccadoro M, Nagler A, Palumbo A.

Blood. 2012 Jan 26;119(4):933-9; quiz 1093. doi: 10.1182/blood-2011-03-344333. Epub 2011 Aug 11.

2.

Aspirin, warfarin, or enoxaparin thromboprophylaxis in patients with multiple myeloma treated with thalidomide: a phase III, open-label, randomized trial.

Palumbo A, Cavo M, Bringhen S, Zamagni E, Romano A, Patriarca F, Rossi D, Gentilini F, Crippa C, Galli M, Nozzoli C, Ria R, Marasca R, Montefusco V, Baldini L, Elice F, Callea V, Pulini S, Carella AM, Zambello R, Benevolo G, Magarotto V, Tacchetti P, Pescosta N, Cellini C, Polloni C, Evangelista A, Caravita T, Morabito F, Offidani M, Tosi P, Boccadoro M.

J Clin Oncol. 2011 Mar 10;29(8):986-93. doi: 10.1200/JCO.2010.31.6844. Epub 2011 Jan 31.

PMID:
21282540
3.

Prophylactic recombinant erythropoietin therapy and thalidomide are predictors of venous thromboembolism in patients with multiple myeloma: limited effectiveness of thromboprophylaxis.

Anaissie EJ, Coleman EA, Goodwin JA, Kennedy RL, Lockhart KD, Stewart CB, Coon SK, Bailey C, Barlogie B.

Cancer. 2012 Jan 15;118(2):549-57. doi: 10.1002/cncr.26302. Epub 2011 Jun 30.

4.

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma.

Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Bladé J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA; International Myeloma Working Group.

Leukemia. 2008 Feb;22(2):414-23. Epub 2007 Dec 20. Review.

PMID:
18094721
5.

Thromboprophylaxis in multiple myeloma patients treated with lenalidomide - A systematic review.

Al-Ani F, Bermejo JM, Mateos MV, Louzada M.

Thromb Res. 2016 May;141:84-90. doi: 10.1016/j.thromres.2016.03.006. Epub 2016 Mar 5. Review.

PMID:
26986753
6.

Clinical and genetic factors associated with venous thromboembolism in myeloma patients treated with lenalidomide-based regimens.

Bagratuni T, Kastritis E, Politou M, Roussou M, Kostouros E, Gavriatopoulou M, Eleutherakis-Papaiakovou E, Kanelias N, Terpos E, Dimopoulos MA.

Am J Hematol. 2013 Sep;88(9):765-70. doi: 10.1002/ajh.23504. Epub 2013 Jul 24.

7.

Effective prophylaxis of thromboembolic complications with low molecular weight heparin in relapsed multiple myeloma patients treated with lenalidomide and dexamethasone.

Klein U, Kosely F, Hillengass J, Hundemer M, Schmitt S, Neben K, Moehler T, Hegenbart U, Ho AD, Goldschmidt H.

Ann Hematol. 2009 Jan;88(1):67-71. doi: 10.1007/s00277-008-0561-1. Epub 2008 Jul 31.

PMID:
18668241
8.

Prophylactic low-dose aspirin is effective antithrombotic therapy for combination treatments of thalidomide or lenalidomide in myeloma.

Niesvizky R, Martínez-Baños D, Jalbrzikowski J, Christos P, Furst J, De Sancho M, Mark T, Pearse R, Mazumdar M, Zafar F, Pekle K, Leonard J, Jayabalan D, Coleman M.

Leuk Lymphoma. 2007 Dec;48(12):2330-7.

PMID:
18067007
9.

Multiple myeloma, venous thromboembolism, and treatment-related risk of thrombosis.

Zamagni E, Brioli A, Tacchetti P, Zannetti B, Pantani L, Cavo M.

Semin Thromb Hemost. 2011 Apr;37(3):209-19. doi: 10.1055/s-0031-1273085. Epub 2011 Mar 31.

PMID:
21455855
10.

The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma.

Baz R, Li L, Kottke-Marchant K, Srkalovic G, McGowan B, Yiannaki E, Karam MA, Faiman B, Jawde RA, Andresen S, Zeldis J, Hussein MA.

Mayo Clin Proc. 2005 Dec;80(12):1568-74.

PMID:
16342649
11.

Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation.

Zangari M, Barlogie B, Anaissie E, Saghafifar F, Eddlemon P, Jacobson J, Lee CK, Thertulien R, Talamo G, Thomas T, Van Rhee F, Fassas A, Fink L, Tricot G.

Br J Haematol. 2004 Sep;126(5):715-21.

PMID:
15327525
12.

Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty.

Eriksson BI, Borris LC, Friedman RJ, Haas S, Huisman MV, Kakkar AK, Bandel TJ, Beckmann H, Muehlhofer E, Misselwitz F, Geerts W; RECORD1 Study Group.

N Engl J Med. 2008 Jun 26;358(26):2765-75. doi: 10.1056/NEJMoa0800374.

13.

Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty.

Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, Misselwitz F, Turpie AG; RECORD3 Investigators.

N Engl J Med. 2008 Jun 26;358(26):2776-86. doi: 10.1056/NEJMoa076016.

14.

Low molecular weight heparins for thromboprophylaxis during induction chemotherapy in patients with multiple myeloma.

Kessler P, Pour L, Gregora E, Zemanova M, Penka M, Brejcha M, Adam Z, Bacovsky J, Fenclova M, Frankova H, Hausdorf P, Walterova L, Heinzova V, Holikova M, Krejci M, Kubackova K, Langrova E, Maisnar V, Meluzinova I, Stavarova Y, Straub J, Scudla V, Gumulec J, Ullrychova J, Hajek R; Czech Myeloma Group.

Klin Onkol. 2011;24(4):281-6.

PMID:
21905619
15.

A retrospective analysis of the effectiveness of low molecular weight heparin for venous thromboembolism prophylaxis in trauma patients.

Gritsiouk Y, Hegsted DA, Schlesinger P, Gardiner SK, Gubler KD.

Am J Surg. 2014 May;207(5):648-51; discussion 651-2. doi: 10.1016/j.amjsurg.2013.12.010. Epub 2014 Jan 30.

PMID:
24560359
16.

Risk of thrombosis with lenalidomide and its prevention with aspirin.

Hirsh J.

Chest. 2007 Jan;131(1):275-7. Review.

PMID:
17218586
17.

Enoxaparin or aspirin for the prevention of recurrent thromboembolism in newly diagnosed myeloma patients treated with melphalan and prednisone plus thalidomide or lenalidomide.

Palumbo A, Rus C, Zeldis JB, Rodeghiero F, Boccadoro M; Italian Multiple Myeloma Network, Gimema.

J Thromb Haemost. 2006 Aug;4(8):1842-5. No abstract available.

18.

Incidence and prophylaxis of venous thromboembolic events in multiple myeloma patients receiving immunomodulatory therapy.

Musallam KM, Dahdaleh FS, Shamseddine AI, Taher AT.

Thromb Res. 2009 Mar;123(5):679-86. doi: 10.1016/j.thromres.2008.09.008. Epub 2008 Nov 6. Review.

PMID:
18992924
19.

Thalidomide-dexamethasone as up-front therapy for patients with newly diagnosed multiple myeloma: thrombophilic alterations, thrombotic complications, and thromboprophylaxis with low-dose warfarin.

Cini M, Zamagni E, Valdré L, Palareti G, Patriarca F, Tacchetti P, Legnani C, Catalano L, Masini L, Tosi P, Gozzetti A, Cavo M.

Eur J Haematol. 2010 Jun;84(6):484-92. doi: 10.1111/j.1600-0609.2010.01434.x. Epub 2010 Feb 23.

PMID:
20192986

Supplemental Content

Support Center